{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67b30ddba16c1d2aa57e604f/6867e364a5162e94233d1500?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Episode 3 (BONUS): Crimes Against Innovation - Gender Bias in Trials vs. The Five-to-Ten-Year Promise","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/67b30ddba16c1d2aa57e604f/1751638850081-592d7462-a4f5-47b5-9b1e-1c7f4656ccc5.jpeg?height=200","description":"<p><strong>In the darkened corridors of laboratories and the silent pages of medical journals, </strong>there are stories rarely spoken about—tales of brilliance that burned too bright, and ideas that strayed into catastrophe. This is—<em>Crimes Against Innovation</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Laurence Woollard</strong> and Dr. <strong>Emma Lane</strong> debate two pressing issues in healthcare: the under-representation of women in clinical trials and the misleading timelines often promised for new treatments. Host Nicola Hill listens to both sides and selects the most impactful “crime” against innovation.</p><p>&nbsp;</p><p>This podcast is produced and funded by UCB.</p><p>Hosted on Acast. See <a href=\"https://acast.com/privacy\" rel=\"noopener noreferrer\" target=\"_blank\">acast.com/privacy</a> for more information.</p><p>&nbsp;</p><p>IE-OT-2500052 – July 2025</p>","author_name":"UCB Biopharma"}